Shares of [finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) are currently up by more than [finviz_code ticker=CXRX item=60 value=”2.04%”] from the open today and are trading at $[finviz_code ticker=CXRX item=65 value=”2.50″]. More than [finviz_code ticker=CXRX item=67 value=”787,596″] shares have exchanged hands compared to an average trading volume of [finviz_code ticker=CXRX item=63 value=”1.50M”]. At the current pps, the market cap stands at $[finviz_code ticker=CXRX item=6 value=”127.54M”]. The stock prices of [finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) are currently trading at [finviz_code ticker=CXRX item=57 value=”-92.86%”] below its 52 week high and [finviz_code ticker=CXRX item=58 value=”47.93%”] above its 52 week low.
[finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) has been in the news for all the right reasons. Recently, [finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) announced that it has paid the second and final installment of its earn-out to Cinven1 relating to Concordia’s October 2015 acquisition of Amdipharm Mercury Limited.
Today’s payment of £72 million, plus interest of approximately £1.5 million, was paid with cash on hand
About Concordia Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. The Company has an international footprint with sales in more than 100 countries, and has a diversified portfolio of more than 200 established, off-patent molecules that make up more than 1,300 SKUs. Concordia also markets orphan drugs through its Orphan Drugs Division, consisting of Photofrin® for the treatment of certain rare forms of cancer.
Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
1 In this press release ‘Cinven’ means, depending on the context, any of or collectively, Cinven Group Limited, Cinven Partners LLP, Cinven (LuxCo1) S.A., Cinven Capital Management (V) General Partner Limited and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by the group.
SOURCE Concordia International Corp.
[finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) is all set to announce its earnings on [finviz_code ticker=CXRX item=68 value=”Feb 13/b”]. As per Zack’s analyst ratings, [finviz_code ticker=CXRX item=2 value=”Concordia International Corp.”] (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) currently has an average brokerage rating of [quandl_code ticker=CXRX item=ZAR|RATING_MEAN value=”3.17″]. On a scale of 1 to 5, a rating of 1 or 2 would indicate a buy, and a rating of 4 or 5 would signify a sell recommendation. A rating of 3 would indicate a hold on the stock. The consensus target price on (NASDAQ:[finviz_code ticker=CXRX item=1 value=”CXRX”]) is $[quandl_code ticker=CXRX item=ZAR|TP_MEAN_EST value=”4.5″] with a high of $[quandl_code ticker=CXRX item=ZAR|TP_HIGH_EST value=”10″] and a low of $[quandl_code ticker=CXRX item=ZAR|TP_LOW_EST value=”1″].
Let’s take a look at the technical analysis.
[intr_chart ticker=CXRX src=”http://www.financialstrend.com/wp-content/uploads/2017/02/25477-CXRX5.png”]
[intr_bto ticker=CXRX content=”ICAgIFRoZSBCYXJjaGFydCBUZWNobmljYWwgT3BpbmlvbiByYXRpbmcgaXMgYSAyNCUgQnV5IHdpdGggYSBXZWFrZXN0IHNob3J0IHRlcm0gb3V0bG9vayBvbiBtYWludGFpbmluZyB0aGUgY3VycmVudCBkaXJlY3Rpb24uICAgICBMb25nZXIgdGVybSwgdGhlIHRyZW5kIHN0cmVuZ3RoIGlzIE1pbmltdW0uICAgICAgICA=”]
The The Exponential Moving Average (EMA) is similar to a simple moving average (average price over a set period) but it utilizes a weighting factor that exponentially declines from the most recent data point (recent prices are weighted higher than oid prices). EMA analysis compares the short term (5 days and 13 days), intermediate term (20 days) and long term (50 days) EMA’s. The respective EMA’s will give bullish signals when trading above trailing EMA’s and below the current price and vice versa. EMA alerts include crossovers (i.e the 5 day EMA crosses above/below the 20 day EMA) and EMA convergencies (5 day EMA equivalent to 13 day EMA). [ema_code ticker=CXRX].
The relative strength index (RSI) is a momentum osciallator that is able to measure the velocity and magnitude of stock price changes. Momentum is calculated as the ratio of positive price changes to negative price changes. The RSI analysis compares the current RSI against neutral(50), oversold (30) and overbought (70) conditions. Alerts will inform you when stocks recede from oversold/overbought levels or breakthrough neutral (50). [rsi_code ticker=CXRX]
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.